XELOX in colorectal cancer: A convenient option for the future?

Expert Review of Gastroenterology and Hepatology

Volumn 5, Issue 1, 2011, Pages 9-19

  Lindsay, Colin R ^a,b   Cassidy, Jim ^a,c  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

cancer; capecitabine; colorectal; oxaliplatin; XELOX

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CETUXIMAB; DIHYDROPYRIMIDINE DEHYDROGENASE; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; THYMIDYLATE SYNTHASE;

ANAPHYLACTOID PURPURA; ARTERY THROMBOSIS; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CATHETER THROMBOSIS; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG CHOICE; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ELDERLY CARE; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LETHARGY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PROTEIN EXPRESSION; QUALITY OF LIFE; RASH; RECOMMENDED DRUG DOSE; SENSORY NEUROPATHY; SKIN DISEASE; THROMBOCYTOPENIA; THROMBOEMBOLISM; VEIN THROMBOSIS; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FLUOROURACIL; HUMANS; TREATMENT OUTCOME;

EID: 79951623511     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.10.90     Document Type: Article

References (104)

1. de Gramont A, Bosset JF, Milan C et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J. Clin. Oncol. 15(2), 808-815 (1997). (Pubitemid 27074252)
2. Köhne CH, Wils J, Lorenz M et al. Randomized Phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J. Clin. Oncol. 21(20), 3721-3728 (2003). (Pubitemid 46606225)
3. Andre T, Colin P, Louvet C et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J. Clin. Oncol. 21(15), 2896-2903 (2003). (Pubitemid 46621839)
4. Miwa M, Ura M, Nishida M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer 34(8), 1274-1281 (1998). (Pubitemid 28342121)
5. Schüller J, Cassidy J, Dumont E et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother. Pharmacol. 45(4), 291-297 (2000). (Pubitemid 30151522)
6. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized Phase III study. J. Clin. Oncol. 19(8), 2282-2292 (2001). (Pubitemid 32366981)
7. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large Phase III study. J. Clin. Oncol. 19(21), 4097-4106 (2001). (Pubitemid 33049527)
8. Scheithauer W, McKendrick J, Begbie S et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, Phase III trial. Ann. Oncol. 14(12), 1735-1743 (2003). (Pubitemid 38029045)
9. Van Cutsem E, Hoff PM, Harper P et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, Phase III trials. Br. J. Cancer 90(6), 1190-1197 (2004). (Pubitemid 38496812)
10. Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N. Engl. J. Med. 352(26), 2696-2704 (2005). (Pubitemid 41007824)
11. Armand JP, Boige V, Raymond E et al. Oxaliplatin in colorectal cancer: an overview. Semin. Oncol. 27(5 Suppl. 10), 96-104 (2000).
12. Díaz-Rubio E, Sastre J, Zaniboni A et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a Phase II multicentric study. Ann. Oncol. 9(1), 105-108 (1998). (Pubitemid 28125772)
13. Machover D, Diaz-Rubio E, de Gramont A et al. Two consecutive Phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann. Oncol. 7(1), 95-98 (1996). (Pubitemid 26051870)
14. Lévi F, Misset JL, Brienza S et al. A chronopharmacologic Phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 69(4), 893-900 (1992).
15. Bertheault-Cvitkovic F, Jami A, Ithzaki M et al. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J. Clin. Oncol. 14(11), 2950-2958 (1996). (Pubitemid 26371453)
16. de Gramont A, Vignoud J, Tournigand C et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur. J. Cancer 33(2), 214-219 (1997).
17. André T, Bensmaine MA, Louvet C et al. Multicenter Phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J. Clin. Oncol. 17(11), 3560-3568 (1999). (Pubitemid 29517928)
18. Maindrault-Goebel F, Louvet C, André T et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur. J. Cancer 35(9), 1338-1342 (1999). (Pubitemid 29397433)
19. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18(16), 2938-2947 (2000). (Pubitemid 30644117)
20. Giacchetti S, Perpoint B, Zidani R et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 18(1), 136-147 (2000). (Pubitemid 30036347)
21. André T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 350(23), 2343-2351 (2004). (Pubitemid 38702845)
22. Kuebler JP, Wieand HS, O'Connell MJ et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J. Clin. Oncol. 25(16), 2198-2204 (2007). (Pubitemid 46954643)
23. Clarke DE, Raffin TA. Infectious complications of indwelling long-term central venous catheters. Chest 97(4), 966-972 (1990). (Pubitemid 20132327)
24. Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J. Clin Oncol. 21(19), 3665-3675 (2003). (Pubitemid 46594061)
25. Extra JM, Espie M, Calvo F et al. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother. Pharmacol. 25(4), 299-303 (1990). (Pubitemid 20014976)
26. Díaz-Rubio E, Evans TR, Tabemero J et al. Capecitabine (Xeloda) in combination with oxaliplatin: a Phase I, dose-escalation study in patients with advanced or metastatic solid tumors. Ann. Oncol. 13(4), 558-565 (2002). (Pubitemid 34461139)
27. Cassidy J, Tabernero J, Twelves C et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J. Clin. Oncol. 22(11), 2084-2091 (2004). (Pubitemid 41095141)
28. Makatsoris T, Kalofonos HP, Aravantinos G et al. A Phase II study of capecitabine plus oxaliplatin (XELOX): a new first-line option in metastatic colorectal cancer. Int. J. Gastrointest. Cancer 35(2), 103-109 (2005). (Pubitemid 41272207)
29. Borner MM, Dietrich D, Stupp R et al. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J. Clin. Oncol. 20(7), 1759-1766 (2002). (Pubitemid 34273264)
30. Yaman E, Uner A, Er O et al. Capecitabine plus oxaliplatin (XELOX) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer. Med. Oncol. 24(4), 431-435 (2007). (Pubitemid 350135937)
31. Moreno-Solórzano I, Ibeas-Rollan R, Monzó-Planella M et al. Two Doses of oxaliplatin with capecitabine (XELOX) in metastatic colorectal cancer. Clin. Colorectal Cancer 6(9), 634-640 (2007). (Pubitemid 47573868)
32. Scheithauer W, Kornek GV, Raderer M et al. Randomized multicenter Phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 21(7), 1307-1312 (2003). (Pubitemid 46606408)
33. Gruenberger B, Tamandl D, Schueller J et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J. Clin. Oncol. 26(11), 1830-1835 (2008).
34. Midgley R, Kerr D. Colorectal cancer. Lancet 353(9150), 391-399 (1999). (Pubitemid 29088178)
35. Fong Y, Fortner J, Sun RL et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann. Surg. 230(3), 309-318 (1999).
36. Choti MA, Sitzmann JV, Tiburi MF et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann. Surg. 235(6), 759-766 (2002). (Pubitemid 34547293)
37. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 22(1), 23-30 (2004). (Pubitemid 41095110)
38. Cassidy J, Clarke S, Díaz-Rubio E et al. Randomized Phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J. Clin. Oncol. 26(12), 2006-2012 (2008).
39. Cassidy J, Clarke S, Diaz-Rubio E et al. XELOX-1/NO16966, a randomized Phase III trial of first-line XELOX compared with FOLFOX4 for patients with metastatic colorectal cancer (MCRC): updated survival and tolerability results. Presented at: ASCO GI Annual Meeting 2009. Chicago, IL, USA, May 29-June 2, 2009 (Abstract 382).
40. Ducreux M, Bennouna J, Hebbar M et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Int. J. Cancer 128(3), 682-690 (2011).
41. Díaz-Rubio E, Tabernero J, Gómez-España A et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J. Clin. Oncol. 25(27), 4224-4230 (2007). (Pubitemid 47548562)
42. Rothenberg ML, Cox JV, Butts C et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized Phase III noninferiority study. Ann. Oncol. 19(10), 1720-1726 (2008).
43. Porschen R, Arkenau HT, Kubicka S et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J. Clin. Oncol. 25(27), 4217-4223 (2007). (Pubitemid 47548561)
44. Grothey A, Deschler B. Kroening H et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) in advanced colorectal cancer (ACRC). Proc. Am. Soc. Clin. Oncol. 21, 129a (2002).
45. Schmoll HJ, Cartwright T, Tabernero J et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J. Clin. Oncol. 25(1), 102-109 (2007). (Pubitemid 350003057)
46. Borner MM, Schoffski P, de Wit R et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur. J. Cancer 38(3), 349-358 (2002). (Pubitemid 34121962)
47. Twelves C, Gollins S, Grieve R et al. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann. Oncol. 17(2), 239-245 (2006). (Pubitemid 43160112)
48. Conroy T, Hebbar M, Bennouna J et al. Quality-of-life findings from a randomised Phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer. Br. J. Cancer. 102(1), 59-67 (2010).
49. Spurna Z, Brancikova D, Urbanek T. Quality of life and patient (pt) preference for oral chemotherapy in metastatic colorectal carcinoma (MCRC): Comparison of XELOX and FOLFOX regimens. Presented at: ASCO Annual Meeting 2008. Chicago, IL, USA, May 30-June 3, 2008 (Abstract 20697).
50. Ward SE, Kaltenthaler E, Cowan J et al. The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. Br. J. Cancer 95(1), 27-34 (2006). (Pubitemid 43980550)
51. Shiroiwa T, Fukuda T, Tsutani K. Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials. Br. J. Cancer 101(1), 12-18 (2009).
52. Perrocheau G, Bennouna J, Ducreux M et al. Cost-minimization analysis of XELOX versus FOLFOX-6 as first-line treatment of metastatic colorectal cancer in France. Presented at: ASCO GI Annual Meeting 2009. Chicago, IL, USA, 29 May-2 June 2009 (Abstract 460).
53. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351(4), 337-345 (2004). (Pubitemid 38944402)
54. Lenz HJ, Van Cutsem E, Khambata-Ford S et al. Multicenter Phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J. Clin. Oncol. 24(30), 4914-4921 (2006). (Pubitemid 46630920)
55. Sobrero AF, Maurel J, Fehrenbacher L et al. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(14), 2311-2319 (2008).
56. Borner M, Koeberle D, Von Moos R et al. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized Phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Ann. Oncol. 19(7), 1288-1292 (2008). (Pubitemid 351911959)
57. Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27(5), 663-671 (2009).
58. Barroso SA, Sanches E, Ferreira JM et al. Preliminary results of an open label, uncontrolled, multicenter, Phase II study evaluating the efficacy and safety of xelox plus cetuximab as first-line therapy in patients with metastatic colorectal cancer. Presented at: ASCO Annual Meeting 2008. Chicago, IL, USA, 30 May-3 June 2008 (Abstract 15010).
59. Heinemann V, Moosmann N, Vehling- Kaiser U et al. XELIRI plus cetuximab versus XELOX plus cetuximab for first-line therapy of metastatic colorectal cancer (CRC): a randomized trial of the AIO CRC Study Group. Presented at: ASCO Gastrointestinal Cancers Symposium 2007. Orlando, FL, USA, 19-21 January 2007 (Abstract 278).
60. Van Cutsem E, Verslype C, Beale P et al. A Phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients. Ann. Oncol. 19(2), 332-339 (2008). (Pubitemid 351201716)
61. Adams RA, Meade AM, Madi A et al. Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. Br. J. Cancer 100(2), 251-258 (2009).
62. Kabbinavar FF, Schulz J, McCleod M et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized Phase II trial. J. Clin. Oncol. 23(16), 3697-3705 (2005).
63. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335-2342 (2004). (Pubitemid 38702844)
64. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25(12), 1539-1544 (2007). (Pubitemid 46733080)
65. Doi T, Boku N, Kato K et al. Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer. Jpn. J. Clin. Oncol. 40(10), 913-920 (2010).
66. Gaspar E, Juarez Marroqui A, Vicent J et al. Bevacizumab plus XELOX as first-line therapy for patients with metastatic colorectal cancer. Presented at: ASCO Annual Meeting 2008. Chicago, IL, USA, 30 May-3 June 2008 (Abstract 15114).
67. Van Cutsem E, Rivera F, Berry S et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann. Oncol. 20(11), 1842-1847 (2009).
68. Saltz LB, Clarke S, Díaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III study. J. Clin. Oncol. 26(12), 2013-2019 (2008).
69. Tournigand C, Samson B, Scheithauer W et al. mFOLFOX-bevacizumab or XELOX-bevacizumab then bevacizumab (B) alone or with erlotinib (E) in first-line treatment of patients with metastatic colorectal cancer (mCRC): interim safety analysis of DREAM study. Presented at: ASCO GI Annual Meeting 2009. Chicago, IL, USA, 29 May-2 June 2009 (Abstract 4077).
70. Ionov Y, Peinado MA, Malkhosyan S et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363(6429), 558-561 (1993). (Pubitemid 23186645)
71. Gryfe R, Kim H, Hsieh ET et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N. Engl. J. Med. 342(2), 69-77 (2000). (Pubitemid 30036597)
72. Aebi S, Kurdi-Haidar B, Gordon R et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 56(13), 3087-3090 (1996). (Pubitemid 26199755)
73. Meyers M, Wagner MW, Hwang HS et al. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res. 61(13), 5193-5201 (2001). (Pubitemid 32681553)
74. Ribic CM, Sargent DJ, Moore MJ et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 349(3), 247-257 (2003). (Pubitemid 36859476)
75. Kim GP, Colangelo LH, Wieand HS et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute- National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J. Clin. Oncol. 25(7), 767-772 (2007). (Pubitemid 350002875)
76. Sargent DJ, Marsoni S, Monges G et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J. Clin. Oncol. 28(20), 3219-3226 (2010).
77. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol. 23(3), 609-618 (2005). (Pubitemid 46224239)
78. Aschele C, Debernardis D, Casazza S et al. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J. Clin. Oncol. 17(6), 1760-1770 (1999). (Pubitemid 29269245)
79. Cascinu S, Aschele C, Barni S et al. Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin. Cancer Res. 5(8), 1996-1999 (1999). (Pubitemid 29399249)
80. Davies MM, Johnston PG, Kaur S et al. Colorectal liver metastasis thymidylate synthase staining correlates with response to hepatic arterial floxuridine. Clin. Cancer Res. 5(2), 325-328 (1999). (Pubitemid 29085185)
81. Corsi DC, Ciaparrone M, Zannoni G et al. Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer. Eur. J. Cancer 38(4), 527-534 (2002). (Pubitemid 34185392)
82. Leichman CG, Lenz HJ, Leichman L et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J. Clin. Oncol. 15(10), 3223-3229 (1997). (Pubitemid 27419335)
83. Shirota Y, Stoehlmacher J, Brabender J et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol. 19(23), 4298-4304 (2001). (Pubitemid 33096777)
84. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J. Clin. Oncol. 22(3), 529-536 (2004). (Pubitemid 41079782)
85. Gusella M, Frigo AC, Bolzonella C et al. Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. Br. J. Cancer 100(10), 1549-1557 (2009).
86. Yen JL, McLeod HL. Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur. J. Cancer 43(6), 1011-1016 (2007). (Pubitemid 46483039)
87. Raida M, Schwabe W, Häusler P et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5?-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clin. Cancer Res. 7(9), 2832-2839 (2001). (Pubitemid 32911393)
88. Van Kuilenburg AB, Meinsma R, Zoetekouw L et al. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 12(7), 555-558 (2002). (Pubitemid 35177085)
89. Boisdron-Celle M, Remaud G, Traore S et al. 5-fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett. 249(2), 271-282 (2007). (Pubitemid 46452935)
90. Spindler KG, Andersen RF, Jensen LH et al. EGF61A>G polymorphism as a predictive marker of clinical outcome to first line capecitabine and oxaliplatin in metastatic colorectal cancer. Ann. Oncol. 21(3), 535-539 (2010).
91. Gatta G, Faivre J, Capocaccia R et al. Survival of colorectal cancer patients in Europe during the period 1978-1989. Eur. J. Cancer 34(14), 2176-2183 (1998). (Pubitemid 29036883)
92. Potosky AL, Harlan LC, Kaplan RS et al. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J. Clin. Oncol. 20(5), 1192-1202 (2002). (Pubitemid 34177424)
93. Sundararajan V, Grann VR, Neugut AI. Population based variation in the use of chemotherapy for colorectal cancer in the elderly. Presented at: ASCO Annual Meeting 1999. Atlanta, GA, USA, 15-18 May 1999 (Abstract 1598).
94. Feliu J, Salud A, Escudero P et al. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br. J. Cancer 94(7), 969-975 (2006).
95. Aparicio T, Desramé J, Lecomte T et al. Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. Br. J. Cancer 89(8), 1439-1444 (2003). (Pubitemid 37386597)
96. Viret F, Bugat R, Ducreux M et al. XELOX regimen in elderly patients with metastatic colorectal cancer (MCRC), a FNCLCC French Collaborative Group GERICO 02 Phase II study. Presented at: ASCO Annual Meeting. Chicago, IL, USA, 1-5 June 2007 (Abstract 19513).
97. Comella P, Natale D, Farris A et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108. Cancer 104(2), 282-289 (2005). (Pubitemid 40993254)
98. De Roock W, Piessevaux H, De Schutter J et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann. Oncol. 19(3), 508-515 (2008). (Pubitemid 351325672)
99. Di Fiore F, Blanchard F, Charbonnier F et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br. J. Cancer 96(8), 1166-1169 (2007). (Pubitemid 46625066)
100. Li?vre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26(3), 374-379 (2008). (Pubitemid 351171687)
101. Li?vre A, Bachet JB, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66(8), 3992-3995 (2006).
102. Haller D, Cassidy J, Tabernero J et al. Randomised Phase III trial of capecitabine + oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (NO16968): impact of age on disease-free survival (DFS) or overall survival (OS). Presented at: ESMO/ECCO Annual Meeting 2009. Berlin, Germany, 20-24 September 2009 (Abstract 5LBA).
103. Lindsay CR, MacPherson IR, Cassidy J. Current status of cediranib: the rapid development of a novel anti-angiogenic therapy. Future Oncol. 5(4), 421-432 (2009).
104. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363(9), 876-878 (2010).